NCT03383406

A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 19 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma

Detailed description

Diffuse Large B-Cell lymphoma is currently used as a standard treatment, with a combination of chemotherapy (R-CHOP), which includes Rituximab. However, the survival rate is very poor if the primary treatment is refractory or relapsed within a year or less. The duration of these patients ' lives is around one year and the five-year survival rate is 15-20 %. Thus, a new treatment strategy is needed to improve the survival of the patient with DLBCL, which are either refractory and relapsed.

Conditions

• Diffuse Large B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy	Every cycle(4weeks) Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion.

Timeline

• Start date: 2016-12-01
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2017-12-26
• Last updated: 2017-12-26